Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Integr Med ; 21(3): 289-301, 2023 05.
Article in English | MEDLINE | ID: mdl-36990846

ABSTRACT

OBJECTIVE: Recent investigations have demonstrated that Polygonum perfoliatum L. can protect against chemical liver injury, but the mechanism behind its efficacy is still unclear. Therefore, we studied the pharmacological mechanism at work in P. perfoliatum protection against chemical liver injury. METHODS: To evaluate the activity of P. perfoliatum against chemical liver injury, levels of alanine transaminase, lactic dehydrogenase, aspartate transaminase, superoxide dismutase, glutathione peroxidase and malondialdehyde were measured, alongside histological assessments of the liver, heart and kidney tissue. A nontargeted lipidomics strategy based on ultra-performance liquid chromatography quadrupole-orbitrap high-resolution mass spectrometry method was used to obtain the lipid profiles of mice with chemical liver injury and following treatment with P. perfoliatum; these profiles were used to understand the possible mechanisms behind P. perfoliatum's protective activity. RESULTS: Lipidomic studies indicated that P. perfoliatum protected against chemical liver injury, and the results were consistent between histological and physiological analyses. By comparing the profiles of liver lipids in model and control mice, we found that the levels of 89 lipids were significantly changed. In animals receiving P. perfoliatum treatment, the levels of 8 lipids were significantly improved, relative to the model animals. The results showed that P. perfoliatum extract could effectively reverse the chemical liver injury and significantly improve the abnormal liver lipid metabolism of mice with chemical liver injury, especially glycerophospholipid metabolism. CONCLUSION: Regulation of enzyme activity related to the glycerophospholipid metabolism pathway may be involved in the mechanism of P. perfoliatum's protection against liver injury. Please cite this article as: Peng L, Chen HG, Zhou X. Lipidomic investigation of the protective effects of Polygonum perfoliatum against chemical liver injury in mice. J Integr Med. 2023; 21(3): 289-301.


Subject(s)
Chemical and Drug Induced Liver Injury , Polygonum , Animals , Mice , Polygonum/chemistry , Lipidomics , Liver , Lipids/pharmacology , Glycerophospholipids/metabolism , Glycerophospholipids/pharmacology , Chemical and Drug Induced Liver Injury/drug therapy , Chemical and Drug Induced Liver Injury/prevention & control , Chemical and Drug Induced Liver Injury/metabolism
2.
Food Chem Toxicol ; 175: 113747, 2023 May.
Article in English | MEDLINE | ID: mdl-36997054

ABSTRACT

This research aimed to explore the protective effect of quercetin against nephrotoxicity induced by four organophosphate pesticide mixtures (PM) using untargeted metabolomics technology in rat kidneys. Sixty male Wistar rats were randomly divided into six groups: control, low-dose quercetin treated (10 mg/kg bw), high-dose quercetin treated (50 mg/kg bw), PM-treated, and two dosages of quercetin + PM-treated. Metabolomics results showed that 17 differential metabolites were identified in the PM-treated group, and pathway analysis revealed that renal metabolic disorders include purine metabolism, glycerophospholipid metabolism, and vitamin B6 metabolism. When high-dose quercetin and PM-treated were administered to rats concurrently, the intensities of differential metabolites were substantially restored (p < 0.01), suggesting that quercetin can improve renal metabolic disorders caused by organophosphate pesticides (OPs). Mechanistically, quercetin could regulate the purine metabolism disorder and endoplasmic reticulum stress (ERS)-mediated autophagy induced by OPs by inhibiting XOD activity. Moreover, quercetin inhibits PLA2 activity to regulate glycerophospholipid metabolism and it could also exert antioxidant and anti-inflammatory effects to correct vitamin B6 metabolism in rat kidneys. Taken together, the high dose of quercetin (50 mg/kg. bw) has a certain protective effect on OPs-induced nephrotoxicity in rats, which provides a theoretical basis for quercetin against nephrotoxicity caused by OPs.


Subject(s)
Insecticides , Kidney Diseases , Pesticides , Rats , Male , Animals , Quercetin/pharmacology , Quercetin/therapeutic use , Pesticides/adverse effects , Organophosphorus Compounds , Rats, Wistar , Antioxidants/pharmacology , Metabolomics , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Kidney Diseases/drug therapy , Insecticides/pharmacology , Oxidative Stress , Organophosphates/adverse effects , Glycerophospholipids/pharmacology , Glycerophospholipids/therapeutic use , Vitamin B 6/pharmacology , Purines
3.
J Anim Physiol Anim Nutr (Berl) ; 107(4): 995-1005, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36353940

ABSTRACT

Milk fat globules (MFGs) surround the triacylglycerol core that composes milk fat. The aim of this study is to induce milk fat depression via dietary conjugated linoleic acid (CLA) supplementation to study MFG size parameters, number and glycerophospholipid composition. Eighteen Holstein dairy cows (136 ± 28 days in milk, 571 ± 37.9 kg body weight, 27.6 ± 2.1 kg milk/day) were selected and randomly assigned to a control or CLA group for a 14-day period. Cows were fed a basal diet (control, n = 8) or the control plus 400 g/day CLA (C18:2 cis-9, trans-11 38.1% and C18:2 trans-10, cis-12 36.8%) (n = 10) for 7 days after which the CLA group was switched to the basal diet for another 7 days along with the control group. Cow performance, milk composition, MFG size and numbers were measured daily. On the seventh day after the start of the experiment, milk samples were identified and the quantification of glycerophospholipid compounds, and RNA were isolated from milk fat samples for a real-time polymerase chain reaction. Compared with control, at Day 7 from the start of feeding, supplemental CLA did not affect milk production (28.09 vs. 28.50 kg/day), dry matter intake (14.9 vs. 15.4 kg/day), or milk protein (3.55/100 vs. 3.70 g/100 ml) and lactose contents (5.11/100 vs. 5.17 g/100 ml). However, although the specific surface area of MFG (2138 vs. 1815 m²/kg) was greater, CLA reduced milk fat content (1.95/100 vs 3.64 g/100 ml on Day 7) and particle size parameters of MFG. The number of MFG gradually decreased until Day 7 of feeding, and then increased by Day 14 (2.96 × 109 on Day 1, 1.63 × 109 on Day 7 and 2.28 × 109 on Day 14) in the CLA group. Compared with control, glycerophospholipid analysis revealed that concentrations of phosphatidylcholine (PC) (e.g., PC [16:0/18:1] 20322 vs. 29793 nmol/L), lysophosphatidylethanolamine (LPE) (e.g., LPE [18:1] 956 vs. 4610 nmol/L) and phosphatidylethanolamine (PE) (e.g., PE [16:0/18:1] 7000 vs. 9769 nmol/L) in milk lipids decreased during CLA feeding. In contrast, concentrations of phosphatidylinositol (PI) (e.g., PI [18:0/18:1] 4052 vs. 1799 nmol/L) and phosphatidylserine (PS) (e.g., PS [18:1/18:2] 9500 vs. 6843 nmol/L) increased. The messenger RNA abundance of fatty acid synthase, diacylglycerol O-acyltransferase 1, glycerol-3-phosphate acyltransferase 4 and phosphate cytidylyltransferase 1, choline, alpha (PCYT1A) were downregulated in the CLA group, confirming published data demonstrating a negative effect of CLA on lipogenesis in the mammary gland. Overall, these results provided evidence for the important role of lipogenic gene expression in the regulation of MFG size, number and glycerophospholipid composition.


Subject(s)
Linoleic Acids, Conjugated , Female , Animals , Cattle , Linoleic Acids, Conjugated/pharmacology , Lactation/physiology , Fatty Acids/metabolism , Phospholipids , Diet/veterinary , Glycerophospholipids/pharmacology , Dietary Supplements/analysis
4.
Journal of Integrative Medicine ; (12): 289-301, 2023.
Article in English | WPRIM | ID: wpr-982679

ABSTRACT

OBJECTIVE@#Recent investigations have demonstrated that Polygonum perfoliatum L. can protect against chemical liver injury, but the mechanism behind its efficacy is still unclear. Therefore, we studied the pharmacological mechanism at work in P. perfoliatum protection against chemical liver injury.@*METHODS@#To evaluate the activity of P. perfoliatum against chemical liver injury, levels of alanine transaminase, lactic dehydrogenase, aspartate transaminase, superoxide dismutase, glutathione peroxidase and malondialdehyde were measured, alongside histological assessments of the liver, heart and kidney tissue. A nontargeted lipidomics strategy based on ultra-performance liquid chromatography quadrupole-orbitrap high-resolution mass spectrometry method was used to obtain the lipid profiles of mice with chemical liver injury and following treatment with P. perfoliatum; these profiles were used to understand the possible mechanisms behind P. perfoliatum's protective activity.@*RESULTS@#Lipidomic studies indicated that P. perfoliatum protected against chemical liver injury, and the results were consistent between histological and physiological analyses. By comparing the profiles of liver lipids in model and control mice, we found that the levels of 89 lipids were significantly changed. In animals receiving P. perfoliatum treatment, the levels of 8 lipids were significantly improved, relative to the model animals. The results showed that P. perfoliatum extract could effectively reverse the chemical liver injury and significantly improve the abnormal liver lipid metabolism of mice with chemical liver injury, especially glycerophospholipid metabolism.@*CONCLUSION@#Regulation of enzyme activity related to the glycerophospholipid metabolism pathway may be involved in the mechanism of P. perfoliatum's protection against liver injury. Please cite this article as: Peng L, Chen HG, Zhou X. Lipidomic investigation of the protective effects of Polygonum perfoliatum against chemical liver injury in mice. J Integr Med. 2023; 21(3): 289-301.


Subject(s)
Animals , Mice , Polygonum/chemistry , Lipidomics , Liver , Lipids/pharmacology , Glycerophospholipids/pharmacology , Chemical and Drug Induced Liver Injury/metabolism
5.
Biochem Biophys Res Commun ; 632: 129-138, 2022 12 03.
Article in English | MEDLINE | ID: mdl-36209581

ABSTRACT

Recently, with increasing awareness of health issues, non-alcoholic fatty liver disease (NAFLD) has become an epidemic attracting global attention. As a serious chronic disease, NAFLD is clinically managed with pharmacological interventions that are usually associated with poor long-term efficacy and adverse effects. In this scenario, traditional Chinese medicine (TCM) characterized by "multiple ingredients-multiple targets-multiple pathways" shows promise as a potential option to treat NAFLD. Zexie decoction (ZXD) is a classical TCM formula that possesses favorable lipid-lowering and anti-inflammatory activities. Accumulating evidence indicates that ZXD displays robust efficacy in treating NAFLD. The effectiveness of ZXD against NAFLD has been evaluated in our previous studies. This study further examines its probable mechanism of action in an in-depth manner using multi-omic analysis based on the gut-liver axis and sheds light on the potential relationship among genes, hepatic lipid metabolites, and gut microbiotas. Totally, 71 differentially expressed genes (34 upregulated and 37 downregulated genes), 31 differential lipid molecules (8 upregulated and 23 downregulated), and 56 differential gut microbiotas (37 upregulated and 19 downregulated) were identified in the ZXD-treated group rats compared with the negative control group rats. Of these, owing to their key role in the association analysis, g_Blautia, g_Romboutsia, and g_Lactobacillus were hypothesized to be crucial gut microbiotas in the ZXD-mediated treatment of NAFLD. These microbiotas were found to synergize with key genes, such as AKR1B8, CCN1, and TNKS2, and hepatic lipid metabolites, such as glycerophospholipid and sphingomyelin, which might play a therapeutic role by regulating fatty acid synthesis, correcting lipid metabolism disorder, or reducing the inflammatory response. Overall, the present study provides fresh insights into the ZXD-mediated treatment of NAFLD, which, in turn, is expected to give a push to the modernization of TCM.


Subject(s)
Gastrointestinal Microbiome , Non-alcoholic Fatty Liver Disease , Rats , Animals , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/genetics , Non-alcoholic Fatty Liver Disease/metabolism , Sphingomyelins/metabolism , Liver/metabolism , Fatty Acids/metabolism , Glycerophospholipids/metabolism , Glycerophospholipids/pharmacology , Glycerophospholipids/therapeutic use , Diet, High-Fat/adverse effects
6.
Appl Microbiol Biotechnol ; 106(9-10): 3707-3720, 2022 May.
Article in English | MEDLINE | ID: mdl-35474485

ABSTRACT

Colitis is generally affected by multiple factors, including the dysbiosis of intestinal microbiota, and may affect organs outside colon through circulation. Pectin, which is an edible polysaccharide widely present in plant cell walls, has been proved in our previous study to possess preventive potentials against acute ulcerative colitis, especially when the esterification degree is less than 50%. This study aimed to clarify the underlying correlations of gut microbiome and serum metabolites with the preventive effects of pectin with different esterification degrees (H121, L13, and L102) against colitis in mice. MiSeq sequencing data showed that symbiotic bacteria especially beneficial Lactobacillus and Bifidobacterium were enriched by pectin intake. Fiber consumers such as Prevotella and Bacteroides actively responded to L13 pectin, particularly under high dosage (L13-H). In addition, the abnormal abundance of Akkermansia associated with colitis would not appear in mice who had been provided with any of the three pectins before dextran sulfate sodium (DSS) treatment. Furthermore, pre-treatment of H121 and L13 pectins could improve the serum glycerophospholipids such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). In contrast, lysophosphatidic acid (LPA) contributing to the glycerophospholipid metabolism pathway was enriched only in the L13-H group, which has been previously proved to be associated with the epithelial barrier and intestinal homeostasis. Positive relationships between the glycerophospholipids and the dominant candidates of intestinal bacteria such as Lactobacillus indicated the joint actions of intestinal microbes and serum metabolites as well as the underlying crosstalks among gut microbiome. Therefore, the results of this research suggested that the preventive effects of low-esterified pectin on DSS-induced colitis were likely to be initiated by the enrichment of probiotics in the gut and serum glycerophospholipids. KEY POINTS: • L13 pectin remarkably improved the diversity of the gut microbiome in healthy mice. • Probiotics were enriched and abnormal Akkermansia was restored by L13 and L102 pectins. • Glycerophospholipid metabolism was significantly enriched by H121 and L13 pectins.


Subject(s)
Colitis , Gastrointestinal Microbiome , Animals , Colitis/chemically induced , Colon , Dextran Sulfate , Disease Models, Animal , Esterification , Glycerophospholipids/pharmacology , Lactobacillus , Mice , Mice, Inbred C57BL , Pectins/pharmacology
7.
World J Urol ; 36(11): 1719-1725, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29767328

ABSTRACT

PURPOSE: TMX-101 and TMX-202 are formulations of toll-like receptor 7 (TLR-7) agonists, under investigation for the treatment of urothelial carcinoma. Our goal was to evaluate the efficacy of intravesical instillations of TMX-101 or TMX-202 in an orthotopic bladder cancer rat model. METHODS: Four groups of 14 rats received an instillation with isogenic AY-27 tumor cells on day 0, starting tumor development. On day 2 and 5, the rats were treated with an intravesical instillation of TMX-101 0.1%, TMX-202 0.38%, vehicle solution or NaCl. On day 12 the rats were sacrificed and the bladders were evaluated histopathologically. RESULTS: No signs of toxicity were seen. The number of tumor-positive rats was 11 of 14 (79%) in the vehicle control group and in the NaCl control group, versus 9 of 14 (64%) in the TMX-101-treated group, and 8 of 14 (57%) in the TMX-20-treated group. The difference between tumor-bearing rats in the treated and control groups was not significant (p = 0.12). Bladder weight was significantly lower for TMX-202-treated rats compared to vehicle (p = 0.005). CONCLUSIONS: TMX-101 and TMX-202 are TLR-7 agonists with antitumor activity. Treatment with TMX-101 and TMX-202 resulted in less tumor-bearing rats compared to vehicle or saline control groups, although not statistically significant. In this aggressive bladder cancer model, a lower number of tumor-positive rats after treatment with TLR-7 agonists indicates activity for the treatment of non-muscle invasive bladder cancer.


Subject(s)
Adenine/analogs & derivatives , Carcinoma, Transitional Cell/drug therapy , Glycerophospholipids/pharmacology , Imiquimod/pharmacology , Immunologic Factors/pharmacology , Toll-Like Receptor 7/agonists , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder/drug effects , Adenine/pharmacology , Adjuvants, Immunologic/pharmacology , Administration, Intravesical , Animals , Carcinoma, Transitional Cell/pathology , Cell Line, Tumor , Disease Models, Animal , Rats , Rats, Inbred F344 , Urinary Bladder/pathology , Urinary Bladder Neoplasms/pathology , Xenograft Model Antitumor Assays
8.
Article in English | MEDLINE | ID: mdl-26242691

ABSTRACT

Glycerophospholipids and sphingolipids participate in a variety of indispensable metabolic, neurological, and intracellular signaling processes. In this didactic paper we review the biological roles of phospholipids and try to unravel the precise nature of their putative healthful activities. We conclude that the biological actions of phospholipids activities potentially be nutraceutically exploited in the adjunct therapy of widely diffused pathologies such as neurodegeneration or the metabolic syndrome. As phospholipids can be recovered from inexpensive sources such as food processing by-products, ad-hoc investigation is warranted.


Subject(s)
Dietary Supplements , Glycerophospholipids/pharmacology , Sphingolipids/pharmacology , Cell Membrane/metabolism , Clinical Trials as Topic , Exercise , Glycerophospholipids/biosynthesis , Glycerophospholipids/therapeutic use , Humans , Metabolic Syndrome/drug therapy , Neurodegenerative Diseases/drug therapy , Sphingolipids/biosynthesis , Sphingolipids/therapeutic use
9.
Br J Pharmacol ; 169(4): 784-93, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23072382

ABSTRACT

BACKGROUND AND PURPOSE: The development of potent and selective inhibitors of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) via DAG lipases (DAGL) α and ß is just starting to be considered as a novel and promising source of pharmaceuticals for the treatment of disorders that might benefit from a reduction in endocannabinoid tone, such as hyperphagia in obese subjects. EXPERIMENTAL APPROACH: Three new fluorophosphonate compounds O-7458, O-7459 and O-7460 were synthesized and characterized in various enzymatic assays. The effects of O-7460 on high-fat diet intake were tested in mice. KEY RESULTS: Of the new compounds, O-7460 exhibited the highest potency (IC50 = 690 nM) against the human recombinant DAGLα, and selectivity (IC50 > 10 µM) towards COS-7 cell and human monoacylglycerol lipase (MAGL), and rat brain fatty acid amide hydrolase. Competitive activity-based protein profiling confirmed that O-7460 inhibits mouse brain MAGL only at concentrations ≥ 10 µM, and showed that this compound has only one major 'off-target', that is, the serine hydrolase KIAA1363. O-7460 did not exhibit measurable affinity for human recombinant CB1 or CB2 cannabinoid receptors (Ki > 10 µM). In mouse neuroblastoma N18TG2 cells stimulated with ionomycin, O-7460 (10 µM) reduced 2-AG levels. When administered to mice, O-7460 dose-dependently (0-12 mg·kg⁻¹, i.p.) inhibited the intake of a high-fat diet over a 14 h observation period, and, subsequently, slightly but significantly reduced body weight. CONCLUSIONS AND IMPLICATIONS: O-7460 might be considered a useful pharmacological tool to investigate further the role played by 2-AG both in vitro and in vivo under physiological as well as pathological conditions.


Subject(s)
Anti-Obesity Agents/therapeutic use , Arachidonic Acids/antagonists & inhibitors , Endocannabinoids/antagonists & inhibitors , Enzyme Inhibitors/therapeutic use , Glycerides/antagonists & inhibitors , Glycerophospholipids/therapeutic use , Lipoprotein Lipase/antagonists & inhibitors , Obesity/drug therapy , Oleic Acids/therapeutic use , Organophosphonates/therapeutic use , Animals , Anti-Obesity Agents/administration & dosage , Anti-Obesity Agents/pharmacology , Arachidonic Acids/metabolism , Behavior, Animal/drug effects , Cell Line , Chlorocebus aethiops , Dose-Response Relationship, Drug , Endocannabinoids/metabolism , Energy Intake/drug effects , Enzyme Inhibitors/pharmacology , Glycerides/metabolism , Glycerophospholipids/administration & dosage , Glycerophospholipids/pharmacology , Humans , Hypothalamus/drug effects , Hypothalamus/enzymology , Hypothalamus/metabolism , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Liver/drug effects , Liver/enzymology , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neurons/enzymology , Neurons/metabolism , Obesity/enzymology , Obesity/metabolism , Oleic Acids/administration & dosage , Oleic Acids/pharmacology , Organophosphonates/administration & dosage , Organophosphonates/pharmacology , Rats , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Sterol Esterase/antagonists & inhibitors , Sterol Esterase/metabolism
10.
Georgian Med News ; (195): 85-7, 2011 Jun.
Article in Russian | MEDLINE | ID: mdl-21778549

ABSTRACT

In this paper, using high-performance liquid chromatography methods were quantitatively and qualitatively identified most biological important high fatty acids, contained in Rkatsiteli grape seed oil of 2010 years crop in Signakhi region of Georgia. The chromatography investigation showed, that the grape seed oil contained 61% linolic acid, 19% oleic, 8% palmitic, 4.5% stearic, 1.4% linolenic and 0.6% arachidonuic acids. In standard diet grape seed oil was added as a food additive (5.0 gr and 10.0 gr on 1.0 kg food). After 15 days fatty acids are carried out from mouse liver (120 inbred mouse), fractioned and using high-performance liquid chromatography the retention values of individual fatty asids are identiced. The investigation showed different sensitivity of components contained in grape seed oil.


Subject(s)
Fatty Acids, Unsaturated/analysis , Fatty Acids, Unsaturated/pharmacology , Food Additives/chemistry , Food Additives/pharmacology , Grape Seed Extract/chemistry , Plant Oils/chemistry , Animals , Cell Membrane/drug effects , Chromatography, High Pressure Liquid , Glycerophospholipids/analysis , Glycerophospholipids/pharmacology , Humans , Linoleic Acid/analysis , Linoleic Acid/pharmacology , Liver/drug effects , Mice , Oleic Acid/analysis , Oleic Acid/pharmacology , Triglycerides/analysis , Triglycerides/pharmacology
11.
J Diet Suppl ; 8(2): 158-68, 2011 Jun.
Article in English | MEDLINE | ID: mdl-22432687

ABSTRACT

BACKGROUND: The components of the nutritional supplement Cognitex have been individually shown to have beneficial effects on cognitive function. We evaluated the efficacy of the nutritional supplement in improving cognitive function in elderly with memory complaints. METHODS: Thirty participants received three capsules of the nutritional supplement per day for 12 weeks in an open label study. Efficacy and safety measures, assessed at baseline, 2 weeks, and 12 weeks of treatment, included cognitive evaluation using a computerized cognitive assessment tool, vital signs measurements, and physical examination. RESULTS: Twenty-six participants completed the 12-week study. A significant improvement in memory abilities (recall, recognition, and spatial short term) was observed following 2 weeks of Cognitex treatment (mean change from baseline: 11.15 ± 2.90, 8.68 ± 2.50, and 19.85 ± 6.19, respectively). Attention (sustained and focused), visual learning, and activities of daily living (executive functions and mental flexibility) were improved as well following this short supplementation period (mean change from baseline: 9.46 ± 3.80, 3.76 ± 1.50, 17.31 ± 5.33, 9.45 ± 3.73, and 9.92 ± 4.08, respectively). After 10 additional treatment weeks, activities of daily living demonstrated an additional statistically significant improvement while the beneficial effect observed for the rest of the tested parameters remained unchanged. CONCLUSIONS: The results indicate that the nutritional supplement may improve cognitive performance in elderly with memory complaints; however, further blinded and placebo-controlled studies are needed. TRIAL REGISTRATION: Clinicaltrials.gov, Identifier: NCT00719953.


Subject(s)
Cognition/drug effects , Dietary Supplements , Lipids/therapeutic use , Memory Disorders/drug therapy , Phytotherapy , Activities of Daily Living , Aged , Attention/drug effects , Executive Function/drug effects , Fatty Acids, Omega-3/pharmacology , Fatty Acids, Omega-3/therapeutic use , Female , Glycerophospholipids/pharmacology , Glycerophospholipids/therapeutic use , Humans , Magnoliopsida , Male , Memory/drug effects , Nootropic Agents/pharmacology , Nootropic Agents/therapeutic use , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Uridine Monophosphate/pharmacology , Uridine Monophosphate/therapeutic use
12.
J Nutr ; 139(12): 2358-64, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19828687

ABSTRACT

An imbalance in (n-6)/(n-3) PUFA has been reported in cystic fibrosis (CF) patients. Glycerophospholipids enriched in docosahexaenoic acid (GPL-DHA) have been shown to regulate the (n-6)/(n-3) fatty acid ratio in the elderly. Here, we tested the effect of GPL-DHA supplementation on PUFA status in F508del homozygous CF mice. GPL-DHA liposomes were administrated by gavage (60 mg DHA/kg daily, i.e. at maximum 1.4 mg DHA/d) to 1.5-mo-old CF mice (CF+DHA) and their corresponding wild-type (WT) homozygous littermates (WT+DHA) for 6 wk. The PUFA status of different tissues was determined by GC and compared with control groups (CF and WT). There was an alteration in the (n-6) PUFA pathway in several CF-target organs in CF compared with WT mice, as evidenced by a higher level of arachidonic acid (AA) in membrane phospholipids or whole tissue (21 and 39% in duodenum-jejunum, 32 and 38% in ileum, and 19 and 43% in pancreas). Elevated AA levels were associated with lower linoleic acid (LA) and higher dihomo-gamma-linolenic acid levels. No DHA deficiency was observed. GPL-DHA treatment resulted in different PUFA composition changes depending on the tissue (increase in LA, decrease in elevated AA, DHA increase, increase in (n-6)/(n-3) fatty acid ratio). However, the DHA/AA ratio consistently increased in all tissues in CF+DHA and WT+DHA mice. Our study demonstrates the effectiveness of an original oral DHA formulation in counter-balancing the abnormal (n-6) fatty acid metabolism in organs of CF mice when administrated at a low dose and highlights the potential of the use of GPL-DHA as nutritherapy for CF patients.


Subject(s)
Arachidonic Acid/metabolism , Cystic Fibrosis/metabolism , Dietary Supplements , Docosahexaenoic Acids/pharmacology , Glycerophospholipids/pharmacology , Linoleic Acid/metabolism , Animals , Cell Membrane/metabolism , Cystic Fibrosis/genetics , Disease Models, Animal , Fatty Acids/analysis , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-6/metabolism , Glycerophospholipids/chemistry , Humans , Intestinal Mucosa/metabolism , Intestines/drug effects , Lipids/chemistry , Lipids/isolation & purification , Lung/drug effects , Lung/metabolism , Mice , Mice, Inbred Strains , Pancreas/drug effects , Pancreas/metabolism , Phospholipids/metabolism , Sequence Deletion
13.
J Biol Chem ; 279(51): 53544-53, 2004 Dec 17.
Article in English | MEDLINE | ID: mdl-15456765

ABSTRACT

This is the first report describing the cloning and characterization of sterol carrier protein-2 (SCP-2) from plants. Arabidopsis thaliana SCP-2 (AtSCP-2) consists of 123 amino acids with a molecular mass of 13.6 kDa. AtSCP-2 shows 35% identity and 56% similarity to the human SCP-2-like domain present in the human D-bifunctional protein (DBP) and 30% identity and 54% similarity to the human SCP-2 encoded by SCP-X. The presented structural models of apo-AtSCP-2 and the ligand-bound conformation of AtSCP-2 reveal remarkable similarity with two of the structurally known SCP-2s, the SCP-2-like domain of human DBP and the rabbit SCP-2, correspondingly. The AtSCP-2 models in both forms have a similar hydrophobic ligand-binding tunnel, which is extremely suitable for lipid binding. AtSCP-2 showed in vitro transfer activity of BODIPY-phosphatidylcholine (BODIPY-PC) from donor membranes to acceptor membranes. The transfer of BODIPY-PC was almost completely inhibited after addition of 1-palmitoyl 2-oleoyl phosphatidylcholine or ergosterol. Dimyristoyl phosphatidic acid, stigmasterol, steryl glucoside, and cholesterol showed a moderate to marginal ability to lower the BODIPY-PC transfer rate, and the single chain palmitic acid and stearoyl-coenzyme A did not affect transfer at all. Expression analysis showed that AtSCP-2 mRNA is accumulating in most plant tissues. Plasmids carrying fusion genes between green fluorescent protein and AtSCP-2 were transformed with particle bombardment to onion epidermal cells. The results from analyzing the transformants indicate that AtSCP-2 is localized to peroxisomes.


Subject(s)
Arabidopsis/metabolism , Carrier Proteins/biosynthesis , Carrier Proteins/chemistry , Agar/chemistry , Amino Acid Sequence , Animals , Antigens, Plant , Binding, Competitive , Boron Compounds/pharmacology , Carrier Proteins/metabolism , Cholesterol/pharmacology , Cloning, Molecular , Computational Biology , Electrophoresis, Polyacrylamide Gel , Ergosterol/pharmacology , Escherichia coli/metabolism , Fluorescence Resonance Energy Transfer , Fluorescent Dyes/pharmacology , Glucosides/pharmacology , Glutathione Transferase/metabolism , Glycerophospholipids/pharmacology , Green Fluorescent Proteins/metabolism , Humans , Lipids/chemistry , Models, Chemical , Models, Molecular , Molecular Sequence Data , Onions , Palmitic Acid/pharmacology , Peroxisomes/metabolism , Phosphatidylcholines/pharmacology , Phylogeny , Plant Proteins/chemistry , Plant Proteins/metabolism , Plasmids/metabolism , Protein Conformation , Protein Structure, Secondary , Protein Structure, Tertiary , RNA/metabolism , Rabbits , Recombinant Proteins/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Sterols/chemistry , Stigmasterol/pharmacology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL